Recent Finacing
Recent Raise
Obsidian Therapeutics is a clinical-stage biotech developing cytoDRiVE/dd destabilizing-domain systems to pharmacologically regulate protein expression in engineered cell and gene therapies, advancing OBX-115 (cytoTIL15) in melanoma and NSCLC trials.
